Targeted therapy acts to sensitize stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer
Combining concurrent chemoradiotherapy with cetuximab or bevacizumab improves treatment outcomes, with manageable toxicity. Given the limited sample size of this study, larger studies such as prospective trials are needed.
Authors
- Ganlu Ouyang (ORCID: https://orcid.org/0000-0003-1375-5560)
- Yuanling Tang
- Xiaolin Sun (ORCID: https://orcid.org/0000-0001-9709-1532)
- Yali Shen (ORCID: https://orcid.org/0000-0001-6416-9516)
- Meijuan Huang (ORCID: https://orcid.org/0000-0002-3390-9697)
- Xin Wang (ORCID: https://orcid.org/0000-0002-5122-2418)
- Zhiping Li (ORCID: https://orcid.org/0000-0001-7513-8272)
- Pei Shu (ORCID: https://orcid.org/0000-0001-8451-6343)
- Ning Liu (ORCID: https://orcid.org/0000-0002-2408-2181)
Institutions
- National Medical Products Administration (CN)
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fonc.2025.1464707
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sichuan University
- West China Hospital, Sichuan University